To include your compound in the COVID-19 Resource Center, submit it here.

Biosimilar insulin glargine: Phase III started

Mylan began the open-label U.S. Phase III INSTRIDE 1 trial to compare once-daily

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE